Rensselaer Polytechnic Institute and Icahn School of


NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai recently announced the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science with medicine. This venture will build on a wealth of shared fundamental research discoveries, explore unique therapeutic innovations in cancer, Alzheimer’s disease, infectious diseases; and tissue degeneration; training a new generation of biomedical leaders; and developing new technologies and processes that improve patient outcomes in unprecedented ways. The CEPM represents an evolution in the successful partnership between Mount Sinai and RPI, which has secured more than $70 million in shared research funding since 2013, 90% of which is provided by the National Institutes of Health.

The common center located at 619 West 54and Street in Manhattan, will drive advances in point-of-care and point-of-use devices and diagnostics; microphysiological discovery and diagnostic platforms; robotic surgery; biomedical imaging; the biomanufacturing of therapeutic products; and artificial intelligence and machine learning applied to biomedical data. These technical advances will improve the quality of life of patients by synergizing cutting-edge expertise in research and education at the crossroads of engineering and medicine.

The center was announced with a signing ceremony at the new site.

“This transformative partnership between Rensselaer and Icahn Mount Sinai recognizes that engineering and engineering sciences are fundamental to understanding biomedical phenomena and are essential to developing the next generation of precision diagnostics and therapeutics, healthcare and well-being, and in training advanced researchers and physicians,” said Shirley Ann Jackson, PhD, President of Rensselaer Polytechnic Institute. “Innovative research is a foundation of Rensselaer because our students, faculty, and graduates continue to change the world through advances in science and technology.This center will continue to fuel medical and scientific discoveries with life-changing impacts around the world.

“From highly sensitive and precise bioimaging systems to the discovery of new drug targets, the major inventions that have shaped modern medicine have emerged from close collaboration between engineers and clinicians,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Chair of Academic Affairs for the Mount Sinai Health System. “CEPM presents a bold new paradigm for the pursuit of this collaboration that we believe will lead to unprecedented advances in science, medicine and human health. Additionally, the PhD program will enable us to attract and equip a new generation of researchers with the interdisciplinary engineering and clinical skills to pursue more innovative and impactful research.

The Center for Precision Medicine and Engineering grew out of the historically collaborative work of Rensselaer and Icahn Mount Sinai researchers in the field of precision medicine, a personalized approach to disease treatment and prevention based on differences biological, environmental and lifestyle of individuals. The CEPM will develop new technologies that will revolutionize the way in which patient care is provided.

“Engineering is the driving force behind a growing number of important medical breakthroughs,” said Jonathan Dordick, PhD, professor at the Institute of Chemical and Biological Engineering at Rensselaer and co-director of CEPM. “The Joint Center for Engineering and Precision Medicine is uniquely positioned to integrate engineering research and education with medicine to develop new diagnostics and treatments at the individual level, making a real difference in the lives of people.

“Ultimately, the outcome of CEPM will be transformative new research projects and innovative technologies that shift clinical paradigms,” said Priti Balchandani, PhD, professor of diagnostic, molecular and interventional radiology, neuroscience and psychiatry at Icahn Mount Sinai and co-director. of the CEPM. “And we believe this collaboration will generate new start-ups and attract business partners that will transform the technologies we pioneer into therapeutic solutions that improve healthcare and have life-changing results for our patients and society. society as a whole.

“The life sciences sector is at the center of New York’s economic and public health future, and this project represents an important step toward that future,” said New York City Mayor Eric Adams. “I would like to thank Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai for their unwavering commitment to New York City. I look forward to the many critical innovations they will produce together.

“Thanks to the innovative and historic partnership of Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai, the new Center for Engineering and Precision Medicine holds tremendous promise for biomedicine. The Center is part of the growing and important biotechnology industry that is essential to our economy and the health of all New Yorkers and Americans. I look forward to supporting the Center for Precision Engineering and Medicine as it grows and makes major contributions to society,” said Congressman Jerrold Nadler.

“This center will revolutionize medical practices for some of our most devastating diseases. At the heart of the city’s vision for life sciences is creating opportunity for all New Yorkers, a goal our mayor works so hard to meet. We have the opportunity to host Rensselaer Polytechnic Institute in New York and, with world-class partner Mount Sinai, watch them change research, make discoveries and ultimately improve patient care, saving lives. said the Deputy Mayor for Economic and Workforce Development. Maria TorresSpringer.

“It’s about helping to care for the sick and improving the lives and care of New Yorkers,” said Andrew Kimball, president and CEO of the New York City Economic Development Corporation. “New York City is proud that these cutting-edge institutions are driving innovation around life sciences on Manhattan’s West Side and helping us set the city on a path to building our future talent. Ultimately, the goal of NYCEDC, like this center, is to stimulate new research and develop our talents to translate them into new businesses, jobs, medicines and cutting-edge technologies. As the Center continues to grow, we are excited about the prospect of a future partnership.

Rensselaer Polytechnic Institute is the first and one of the most renowned technological research universities in the country. Rensselaer researchers are internationally recognized for their expertise in biotechnology and biomanufacturing; neuromodulation; tissue engineering, bioinformatics, robotics, devices and microfabrication; and artificial intelligence, machine learning and high performance computing.

Icahn Mount Sinai is the academic arm of the Mount Sinai Health System, which provides world-class medical and research training and education, conducts clinical trials with data available from nearly 4 million patients, and translates basic research and biomedical into commercial products.

CEPM will focus on three critical research areas at the interface of engineering and medicine:

  • Neuroengineering, which exploits minimally invasive control and regulation of neural circuits to target neurodegenerative diseases; brain-computer/network analysis; neuro-diagnosis; and computational neurobiology
  • Immunoengineering, which focuses on the development of designer immune cells; microbiome engineering; anti-infectives on demand; and synthetic vaccines to help our bodies fight cancer and infectious diseases
  • Regenerative and Restorative Medicine, which encompasses personalized tissue repair and regeneration on demand; organoids (3D tissue culture that mimics simplified organ function); and cellular reprogramming

To foster innovation, CEPM will develop a joint five-year doctorate in precision engineering and medicine that will equip a new generation of researchers with basic biological sciences, data analytics, and engineering knowledge and skills to pursue breakthroughs. in medical science. The development of master’s and certificate programs will expand CEPM’s academic mission and facilitate research that spans all aspects of disease mechanisms, data, and technologies, from molecular to human dimensions. These programs include a joint doctorate in engineering and precision medicine, a doctorate in the School of Engineering or the School of Science at Rensselaer with a concentration in engineering and precision medicine, and a doctorate with a master’s degree or certificate combined in entrepreneurship.

Other key leaders include Deepak Vashishth, PhD, Associate Director of CEPM and Director of the Center for Biotechnology and Interdisciplinary Studies and Professor of Biomedical Engineering at Rensselaer; and CEPM senior advisors Zahi Fayad, PhD, director of the Institute for Biomedical Engineering and Imaging at Icahn Mount Sinai and Scott L. Friedman, MD, Fishberg Professor of Medicine and Dean of Therapeutic Discovery at Icahn Mount Sinai.

“Health care is a human right and everyone, regardless of postcode, should have access to world-class care. Today’s announcement that two world-class institutions have joined forces to bring the very latest innovations in biotech research and design to New York City will further the city’s growth as a biotech hub and revolutionize the future of medicine, from custom tissue design to incisionless neurosurgery,” said Lynn Schulman, Council Member and Chair of the City Council Health Committee.

“I am thrilled to welcome the brand new Mount Sinai Medical Center to the Council’s 6th District, which will further strengthen New York City’s position as an international leader in life sciences and healthcare. partnership between Rensselaer Polytechnic Institute and the Icahn School of Medicine will focus on some of the toughest health challenges we face and serve as a model for medical research and innovation,” said Gale A. Brewer (D- 06), member of the Council.

A media clip accompanying this announcement is available by clicking on the image or link below:

Rensselaer Polytechnic Institute
Deanna Cohen
[email protected]

Source link


Comments are closed.